BOARD OF DIRECTORS
Board of Directors
Board of Directors
Anca Maria Copaescu
Anca Maria Copaescu
Anca is the dynamo that powers Strategikon. She envisioned and created Clinical Maestro™ based on more than 15 years’ experience in the clinical research industry with both sponsors and service providers.
As Head of Clinical Outsourcing and Analytics at BioMarin Pharmaceuticals, Anca managed and advanced the company’s global outsourcing, vendor management and clinical analytics functions. At two of the top global clinical research organizations (CROs), PharmaNet Development Group (now inVentiv) and Icon plc, Anca drove strategic corporate development activities. These positions afforded her with unique insights into the competitive advantages of CROs. Anca is also a serial entrepreneur. After winning first prize in the prestigious Steven Burrill Business Plan Competition, she co-founded eMetagen Corporation, an early stage drug discovery company that was the first start-up partnership between University of Wisconsin-Madison and a student. Anca also co-founded Ponderas Academic Hospital, now acquired by Regina Maria Health Network, in Bucharest, Romania.
Anca is a creative driven strategist focused on efficiency and innovation. She has relentlessly pursued improvements to key clinical development processes like clinical study planning, outsourcing and financial management. Frustrated by the shortcomings of every available technology solution, she decided to build a better one. Clinical Maestro™ addresses the entire clinical study financial process: from planning, to outsourcing, to the end of the clinical contract and study analytics.
Anca received her BSc in International Business from Academy of Economic Sciences in Bucharest Romania, an MBA from University of Pittsburgh Katz Business School and Czech Management School and an MSc in Applied Corporate Finance from University of Wisconsin Madison. She is a passionate reader, writer, history lover and global traveler.
Mark Di Ianni
Chairman of Board, Co-founder
Mark Di Ianni
Mark Di Ianni is an experienced executive and “company builder”. He has worked for Pharmaceutical/Biotechnology product companies early and late career and has provided consulting services to the industry for over 30 years through the development and management of several independent Pharmaceutical Service firms.
Mr. Di Ianni’s senior management experience includes operations, business development and strategic planning on an international basis. Mr. Di Ianni started his pharmaceutical career at Roche pharmaceuticals and then entered the fledgling Contract Research Organization (CRO) industry when he joined Besselaar Associates where he was a principal. Besselaar became the “market maker” for a multi-billion dollar service industry. Mark has held P&L responsible positions as COO/EVP and Board Member of SCIREX, a CNS focused CRO, COO of SYNARC a company providing medical imaging services for clinical trials, and President of Early Stage Development at Pharmanet Development Group, a publically traded CRO. Mark retired from BioMarin, a products company for rare genetic diseases, in 2015 where he was a Group Vice President.
Mark holds a BS degree (Electrical Engineering) and BA degree (Psychology-experimental emphasis) from Lafayette College, and an MA (Psychology-experimental emphasis) from Fairleigh Dickinson University.
former CEO BioClinica
Mark brings a wealth of both industry knowledge and experience in developing technology companies. Mark served as CEO, President and Board of Directors member of BioClinica from 1997 to 2015. Over that 17 year period, Mark guided BioClinica from a $2 million dollar revenue 30 person single product company to a 1,200 person multi-product/multi-sector company with revenues of over $200 million dollars. Although diverse, all of BioClinicas’ activities were focused on helping pharmaceutical, bio-technology and medical device companies getting their products approved.
Prior to BioClinica, Mark’s experience included 6 years at Medical Economics Data where he had progressively increased responsibilities. Titles included Vice President of Operations, Vice President of US Subsidiaries and President of the International Group.
Mr. Weinstein received his Bachelor of Arts degree from University of Virginia and his Masters in Business Administration (MBA) from The College of William and Mary
Mr. Codeanne is a multi-faceted, results-oriented executive with significant leadership, board, operational and transaction-related experience (buy and sell side) and a proven track record of organizing and mobilizing teams to strategically focus and develop businesses, penetrate new markets, increase profit margins and improve stakeholder returns. Mr. Codeanne has an advanced degree with extensive domestic and international experience in general business and operations management, financial operations, business analysis, corporate governance and reporting for publicly traded and venture/private equity backed organizations.
Mr. Codeanne was a member of the Board of Directors, Audit Committee Chairman, and member of Nominating Committee of Cornerstone Therapeutics Inc. (NASDAQ: CRTX)(now Chiesi USA), a specialty pharmaceutical company from October 2008 through January 2014. Mr. Codeanne previously served as a member of the Compensation Committee for a four-year period and was a member of the Special Committee charged with evaluating and consummating the ultimate sale of the business to Chiesi Farmaceutici in January 2014.
Mr. Codeanne was most recently the Chief Financial Officer (“CFO”) of Oxford Performance Materials, a recognized leader in advanced materials science that develops proprietary material, process and application technologies and applies high performance additive manufacturing (HPAM™) to produce fully functional end-use structural parts for the aerospace, industrial, and biomedical industries. Mr. Codeanne was instrumental in the sale of the aerospace assets to Hexcel Corporation.
Prior to Oxford Performance Materials, Mr. Codeanne was the Chief Operating Officer (“COO”) and CFO of Premier Research, an international professional services organization with over 1,000 employees providing clinical development services to the pharmaceutical, biotechnology and medical device industries. Mr. Codeanne was instrumental in turning around the company’s operational and financial performance and converting substantial operating losses into operating income over a three-year period. Mr. Codeanne also served as a member of the Board of Directors of Premier Research.
Prior to Premier Research, Mr. Codeanne was the COO and CFO of Oncopartners, a venture backed, specialized international oncology contract research organization. Mr. Codeanne was responsible for all day to day operations including oversight of clinical operations, business development, and finance and administration as well as identification, oversight and execution of strategic growth initiatives. Mr. Codeanne served as the CFO of Averion International Corp., a publically traded international contract research organization, (“Averion”) from December 2006 through April 2008 where he was responsible for all treasury, finance, mergers and acquisition, accounting, SEC reporting, human resources, information technology, contract and proposals, legal, and risk management functions. As CFO of Averion International, he doubled the company’s size through the financing, acquisition and integration of a European-based CRO. Prior to being appointed as CFO of Averion, from 2002 through July 2006, Mr. Codeanne was the CFO of SCIREX Corporation LLC (“SCIREX”), where he was responsible for all finance, treasury, accounting, human resources, information technology, risk management and facilities management functions. At SCIREX Corporation, he was a key member of the leadership team that grew the business from under $10MM in revenue to over $150MM. Mr. Codeanne led the sale of SCIREX to Premier Research in 2006.
Mr. Codeanne obtained an MBA from the University of Connecticut with a concentration in finance and a Bachelor of Science degree in Accounting from Fairfield University. Mr. Codeanne is a member of the American Institute of Certified Public Accountants.
Angel Investor, Patent Attorney
Board of Directors
Robert Hess is an angel investor, IP attorney and strategic advisor focusing primarily in pharmaceuticals, medtech and B2B SaaS. He is a member of the Life ScienceAngels (LSA), Band of Angels, and Tech Coast Angels, and serves as co-chair of the Digital Health committee at the Life Science Angels.
Previously, Mr. Hess held both in-house and private practice positions as a patent attorney, primarily prosecuting patents in the biotechnology and medical devicefields, including: Solazyme, Boston Biomedica, BioSeq, Sunstein Kann Murphy & Timbers, Biomarin Pharmaceutical, and Leydig, Voit & Mayer.
He holds a B.S. in Biochemistry from Cornell University, a Ph.D. in Molecular Biophysics from University of Wisconsin – Madison, and a J.D. from Suffolk UniversityLaw School.
Osage Venture Partners
Nate joined Osage Venture Partners in 2008 and as Managing Partner oversees investment and portfolio management activities. He serves on the Board of Directors of BA-Insight, DrayNow, HiveIO, Malbek, Noodle Partners, RackWare, RiskLens, Semantic AI, and Sidecar. In addition, Nate is on the Board of Directors and the Executive Committee of the Philadelphia Alliance for Capital and Technology (PACT), where he previously served as Chairman of the Board, and he serves on the Board of Directors and the Executive Committee of Ben Franklin Technology Partners of Southeastern Pennsylvania, a state-supported early stage seed fund. Nate is a frequent speaker and panelist at venture events and is actively involved with numerous venture focused organizations including PACT, NJTC, and MAVA.
Prior to joining Osage, Nate was President and CEO of Verticalnet, a publicly traded SaaS solutions provider, which was sold in January 2008 to Italy-based BravoSolution. Earlier, Nate was a Partner at Mercer Management Consulting (now Oliver Wyman) and led both the San Francisco and the Hong Kong offices. He is a graduate of Brown University and of the Stanford Graduate School of Business where he graduated with honors.
The experts at Strategikon developed Clinical Maestro out of a combination of love and frustration. The system was developed and nurtured by financial and clinical business operations executives with both Sponsor and Provider experience. Our founders believed there had to be a better way — and so they created one.
<a href=”https://strategikondev.wpengine.com/for-sponsors/”>FOR SPONSORS</a><br />
<a href=”https://strategikondev.wpengine.com/for-services-providers/”>FOR SERVICE PROVIDERS</a><br />
<a href=”https://strategikondev.wpengine.com/resources/”>RESOURCES</a><br />
<a href=”https://strategikondev.wpengine.com/press-releases/”>NEWS & EVENTS</a><br />
<a href=”https://strategikondev.wpengine.com/about-us/”>ABOUT US</a><br />